Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics-Reference-Cited by-同舟云学术

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics

Published:2020-04 Issue:04 Volume:80 Page:391-398
ISSN:0016-5751
Container-title:Geburtshilfe und Frauenheilkunde
language:de
Short-container-title:Geburtshilfe Frauenheilkd

Author:

Lüftner Diana¹,Schneeweiss Andreas²,Hartkopf Andreas D.³,Müller Volkmar⁴,Wöckel Achim⁵,Janni Wolfgang⁶,Ettl Johannes⁷,Belleville Erik⁸,Schütz Florian⁹,Thill Marc¹⁰,Huober Jens⁶,Fasching Peter A.¹¹,Kolberg Hans-Christian¹²,Pöschke Patrik¹¹,Welslau Manfred¹³,Overkamp Friedrich¹⁴,Tesch Hans¹⁵,Fehm Tanja N.¹⁶,Lux Michael P.¹⁷

Affiliation:

1. Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany

2. National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital and German Cancer Research Center, Heidelberg, Germany

3. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany

4. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

5. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

6. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

7. Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

8. ClinSol GmbH & Co KG, Würzburg, Germany

9. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany

10. Agaplesion Markus Krankenhaus, Frauenklinik, Frankfurt, Germany

11. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

12. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

13. Onkologie Aschaffenburg, Aschaffenburg, Germany

14. OncoConsult Overkamp GmbH, Berlin, Germany

15. Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany

16. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

17. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany

Abstract

AbstractFor patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynecology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1111-8775.pdf

Reference37 articles.

1. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer;S A Im;N Engl J Med,2019

2. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3;D J Slamon;J Clin Oncol,2018

3. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer;D J Slamon;N Engl J Med,2019

4. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial;G W Sledge;JAMA Oncol,2019

5. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation;J K Litton;N Engl J Med,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows;Scientific Reports;2023-01-07

2. Pectoralis muscle index might be a factor associated with frailty in older women with breast cancer;Turkish Journal of Medical Sciences;2023-01-01

3. Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2022-03

4. Update Mammakarzinom 2021 Teil 1 – Prävention und frühe Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2021-12

5. Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis;Geburtshilfe und Frauenheilkunde;2021-11-18